Pharvaris (NASDAQ:PHVS) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Pharvaris (NASDAQ:PHVS) posted its quarterly earnings results on Thursday. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.04, Zacks reports.

Pharvaris Stock Down 1.6%

PHVS stock traded down $0.55 during midday trading on Friday, hitting $33.28. The company’s stock had a trading volume of 92,625 shares, compared to its average volume of 452,374. Pharvaris has a 52-week low of $23.01 and a 52-week high of $43.25. The firm has a market capitalization of $2.18 billion, a P/E ratio of -10.91 and a beta of -2.48. The firm has a 50-day simple moving average of $33.29 and a 200-day simple moving average of $31.29.

Analysts Set New Price Targets

A number of brokerages have recently commented on PHVS. Oppenheimer reaffirmed an “outperform” rating on shares of Pharvaris in a research note on Friday, October 23rd. New Street Research set a $60.00 price objective on Pharvaris in a research note on Friday, August 14th. Royal Bank Of Canada upped their price target on Pharvaris from $52.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday, September 9th. HC Wainwright reaffirmed a “buy” rating on shares of Pharvaris in a research note on Tuesday, October 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research report on Thursday, October 15th. Fourteen investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $59.53.

Insider Buying and Selling at Pharvaris

In other news, Director Viviane Monges sold 11,969 shares of the stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $33.05, for a total value of $395,575.45. Following the sale, the director directly owned 5,500 shares in the company, valued at approximately $181,775. This trade represents a 68.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO David Nassif sold 6,000 shares of the stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $36.47, for a total value of $218,820.00. Following the completion of the sale, the chief financial officer directly owned 114,300 shares in the company, valued at $4,168,521. This represents a 4.99% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 510,810 shares of company stock valued at $18,563,973. Insiders own 11.84% of the company’s stock.

Pharvaris Company Profile

Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on developing oral treatments for hereditary angioedema (HAE) and other conditions involving bradykinin-mediated swelling. The company was founded in 2015 and is based in Leiden, the Netherlands. Its lead candidate, deucrictibant, is an oral small-molecule antagonist of the bradykinin B2 receptor. Pharvaris is studying the candidate in different formulations for both on-demand treatment of HAE attacks and prevention of attacks.